证券代码：002940 证券简称：昂利康 公告编号：2025-056 浙江昂利康制药股份有限公司 关于获得药品注册证书的公告 三、对公司的影响 本次西格列汀二甲双胍缓释片获得药品注册证书，将进一步丰富公司产品管 线。由于医药行业的特殊性，药品的销售容易受到国家政策、市场环境变化等因 素影响，具体销售情况存在较大不确定性。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，浙江昂利康制药股份有限公司（以下简称"公司"）收到国家药品监 督管理局（以下简称"国家药监局"）签发的西格列汀二甲双胍缓释片《药品注 册证书》，现将有关情况公告如下： | 药品通用名称 | 西格列汀二甲双胍缓释片 | | --- | --- | | 主要成份 | 磷酸西格列汀和盐酸二甲双胍 | | 剂型 | 片剂 | | 申请事项 | 药品注册（境内生产） | | 注册分类 | 化学药品 3 类 | | 规格 | 磷酸西格列汀 50mg（按 C₁₆H₁₅F₆N₅O 计）与盐酸二甲 | | | 双胍 500mg | | 受理号 | CYHS2400188、CYHB2500250 | | 药品 ...

| | 买入金额最大的前5名 | | | | | | --- | --- | --- | --- | --- | --- | | 序号 | | 交易营业部名称 | | 买入金额(万) | 占总成交比例 | | 1 | 机构专用 | | 1414次 43.42% 2 | 8269.79 | 7.10% | | 2 | 机构专用 | Castmoney.com | 1414次 43.42% b | 3797.68 | 3.26% | | 3 | 机构专用 | | 1414次 43.42% | 3490.92 | 3.00% | | 4 | 机构专用 | | 1414次 43.42% | 2990.94 | 2.57% | | 5 | 机构专用 | | 1414次 43.42% | 1913.61 | 1.64% | | | 卖出金额最大的前5名 | | | | | | 序号 | 交易营业部名称 | | 买入金额(万) | 占总成交比例 | | --- | --- | --- | --- | --- | | 1 | 机构专用 | 1414次 43.42% 2 | 3490.92 | 3.00% | | 2 | 中信 ...

昂利康今日涨10.00%，成交额11.65亿元，换手率11.32%，盘后龙虎榜数据显示，5家机构专用席位净买 入1.84亿元，有1家机构专用席位净卖出1147.94万元。 ...

截至收盘，上证指数报收3573.21点，下跌1.18%；深证成指收于11009.77点，下跌1.73%；创业板指下 跌1.66%；科创50指数下跌1.01%。 | 002940 | 昂利康 | 57.20 | 11.32 | 67.85 | 3880.99 | 医药生物 | | --- | --- | --- | --- | --- | --- | --- | | 600828 | 茂业商业 | 4.66 | 5.07 | 813.93 | 3792.90 | 商贸零售 | | 600774 | 汉商集团 | 11.33 | 8.01 | 322.68 | 3655.95 | 医药生物 | | 002799 | 环球印务 | 9.24 | 9.38 | 352.96 | 3261.36 | 轻工制造 | | 603516 | 淳中科技 | 60.48 | 11.90 | 52.57 | 3179.43 | 计算机 | | 001318 | 阳光乳业 | 18.14 | 18.45 | 158.69 | 2878.64 | 食品饮料 | | 603273 | 天元智能 | 21.09 | 38.88 | 122 ...

Market Overview - The A-share market experienced a decline with the Shanghai Composite Index falling by 1.18%, the Shenzhen Component Index down by 1.73%, and the ChiNext Index decreasing by 1.66% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 1.94 trillion yuan, an increase of 91.7 billion yuan compared to the previous trading day, with over 4,200 stocks declining [1][2] Sector Performance - Sectors such as steel, energy metals, coal mining and processing, photovoltaic equipment, and film and television cinema saw declines, while the liquid cooling server sector showed strong performance [4] - The innovative drug concept continued to perform well, with several stocks including Nanxin Pharmaceutical, Anke Bio, and Aoxiang Pharmaceutical hitting the daily limit [4] - The liquid cooling server concept had multiple stocks, including Yingweike and Icewheel Environment, reaching the daily limit [4][5] Capital Flow - Major funds saw net inflows in sectors like banking, computers, and traditional Chinese medicine, while there were net outflows in mining, paper printing, and electronic components [6] - Specific stocks such as 360, Yidian Tianxia, and Yongyou Network received net inflows of 1.133 billion yuan, 889 million yuan, and 881 million yuan respectively [6] - Conversely, Baogang Group, Dongfang Fortune, and CATL faced net outflows of 1.868 billion yuan, 1.697 billion yuan, and 1.663 billion yuan respectively [6] Institutional Insights - Galaxy Securities suggests not to make bullish moves while the Shanghai Composite Index is below the 5-day moving average, indicating a high probability of filling the gap [6] - Everbright Securities notes that market sentiment remains active, with fluctuations being a normal adjustment within the trend [7] - CITIC Securities maintains that the index is expected to continue its upward trend despite short-term fluctuations [7]

Group 1 - The core point of the article is that Anglikon has received approval for its Mesobam injection, which is intended for the treatment of acute skeletal muscle pain, potentially enhancing the company's product pipeline [1] - As of July 31, the stock price of Anglikon reached 57.20 yuan, with a trading volume of 8.22 billion yuan and a turnover rate of 8.08%, resulting in a total market capitalization of 115.39 billion yuan [1] - The approval for the drug includes a registration certificate from the National Medical Products Administration, valid until July 28, 2030, and is considered equivalent to passing the consistency evaluation [1] Group 2 - The sales of the newly approved drug may be influenced by policy and market environment, indicating potential uncertainties in revenue generation [1]

截至3月31日，昂利康股东户数1.23万，人均流通股1.51万股。 2025年1月-3月，昂利康实现营业收入3.46亿元，同比减少15.31%；归属净利润1590.61万元，同比减少 43.63%。 7月31日，昂利康盘中10.0%涨停，截至11:26，报57.2元/股，成交8.16亿元，换手率8.03%，总市值 115.39亿元。 资料显示，浙江昂利康制药股份有限公司位于浙江省嵊州市嵊州大道北1000号，公司是一家集医药中间 体、原料药和制剂研发生产于一体的现代化制药企业，主要产品涵盖抗感染、心血管、麻醉镇痛等多个 治疗领域，并已建立完整的医药产业链。公司拥有多个生产基地和10余家控股子公司，是全球最大α-酮 酸原料药生产商，核心产品进入国家集中采购，近年来持续位居中国医药行业前200位。 ...

Group 1 - The core point of the article is that Anglikon has received the drug registration certificate for Mesobam Injection from the National Medical Products Administration [2] Group 2 - The announcement was made on the evening of July 30 [2] - The registration certificate is a significant regulatory milestone for the company [2] - This development may enhance the company's product portfolio and market position [2]

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing a significant rebound, with numerous stocks doubling in value and a strong performance from innovative drug companies, indicating a potential for continued growth and investment opportunities [1][2][3]. Group 1: Market Performance - As of July 29, 2023, the pharmaceutical sector has seen 42 stocks double in value this year, with Shuyatain leading at a 560% increase [1]. - Eight stocks, including Saifen Technology and Yipin Hong, have risen over 200%, while over 30 stocks have increased by more than 100% [1]. Group 2: Fund Performance - The surge in the pharmaceutical sector has led to significant gains in several pharmaceutical-themed funds, with many achieving over 100% returns in the past year [2]. - Fund managers believe that innovative drugs are likely to gain traction due to high demand and the upcoming product launches from various A-share and H-share companies [2]. Group 3: Industry Insights - Analysts highlight that the innovative drug sector is entering a golden development phase, supported by short-term performance from research outcomes and long-term benefits from aging populations and health demand upgrades [2]. - The innovative drug sector is seen as the most promising sub-industry within pharmaceuticals, with a clear growth trajectory and investment potential [3]. Group 4: Future Outlook - The innovative drug sector is expected to benefit from a combination of policy support and fundamental growth, leading to a revaluation of the sector [3]. - Analysts recommend continued investment in specific segments such as CRO & CDMO, GLP-1, and unique raw materials, which are anticipated to show strong performance [3].

Core Viewpoint - The company, Anglikang (002940.SZ), has received a drug registration certificate for Meisobam Injection from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for acute musculoskeletal pain [1] Company Summary - Anglikang has announced the receipt of a drug registration certificate for Meisobam Injection, which is primarily used for the treatment of acute skeletal muscle pain or discomfort [1]